SCHEMBL2510327

SCHEMBL2510327

CC(N)c1nc2cccc(C(=O)NC(C)(C)C)c2n1C1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
SYK P43405 1/20 0.36
EGFR P00533 1/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 2/20 0.34
JAK1 P23458 3/20 0.34
JAK2 O60674 3/20 0.34
HTR4 Q13639 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2508093 1.00 MAPT (0.38) MAPTTP53MEN1KMT2AALDH1A1
SCHEMBL2505347 0.88 TP53 (0.39) TP53ALDH1A1HTR3EHTR3BHTR3A
SCHEMBL2508692 0.88 TP53 (0.39) TP53ALDH1A1HTR3EHTR3BHTR3A
SCHEMBL2510511 0.87 KDM4E (0.45) MAPTKMT2AALDH1A1HTR3EHTR3B
SCHEMBL2510509 0.87 KDM4E (0.45) MAPTKMT2AALDH1A1HTR3EHTR3B
SCHEMBL2505515 0.84 TP53 (0.41) TP53ALDH1A1HTR3EHTR3BHTR3A
SCHEMBL2505172 0.83 KDM4E (0.42) TP53KMT2AHTR3EHTR3BHTR3A
SCHEMBL2505167 0.83 KDM4E (0.42) TP53KMT2AHTR3EHTR3BHTR3A
SCHEMBL12264153 0.81 MAPT (0.38) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL2507261 0.78 PIK3CD (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575183-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2013-11-05 US disclosed
EP-2552908-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2013-02-06 EP disclosed
WO-2011123751-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-10-06 WO disclosed
US-20110245257-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245257-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 MAPT 3355/4885TP53 283/4885MEN1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.